S
Steven A. Pergam
Researcher at Fred Hutchinson Cancer Research Center
Publications - 152
Citations - 5450
Steven A. Pergam is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 27, co-authored 133 publications receiving 4266 citations. Previous affiliations of Steven A. Pergam include University of Washington & University of New Mexico.
Papers
More filters
Journal ArticleDOI
Respiratory viruses in hematopoietic cell transplant candidates: impact of preexisting lower tract disease on outcomes
Yae Jean Kim,Alpana Waghmare,Hu Xie,Leona Holmberg,Steven A. Pergam,Keith R. Jerome,Wendy M. Leisenring,Chikara Ogimi,Angela P Campbell,Janet A. Englund,Michael Boeckh +10 more
TL;DR: The presence of LRD due to common respiratory viruses, including HRV, before myeloablative allogeneic HCT was associated with increased mortality and hospitalization, and improved management strategies for pretransplant LRD are warranted.
Journal ArticleDOI
Association of Physician Orders for Life-Sustaining Treatment With Inpatient Antimicrobial Use at End of Life in Patients With Cancer.
Olivia S Kates,Olivia S Kates,Elizabeth M Krantz,Juhye M. Lee,John Klaassen,Jessica Morris,Irina Mezheritsky,Ania Sweet,Ania Sweet,Frank Tverdek,Frank Tverdek,Elizabeth T. Loggers,Elizabeth T. Loggers,Elizabeth T. Loggers,Steven A. Pergam,Steven A. Pergam,Steven A. Pergam,Catherine Liu,Catherine Liu,Catherine Liu +19 more
TL;DR: A single-center, retrospective cohort study of adult patients at a cancer center who died between January 1, 2016, and June 30, 2019 was conducted to determine whether Washington State Physician Orders for Life Sustaining Treatment (POLST) form completion or antimicrobial preferences documented therein correlate with subsequent inpatient antimicrobial prescribing at end of life as mentioned in this paper.
Book ChapterDOI
Infections in Leukemia and Hematopoietic Stem Cell Transplantation
TL;DR: Improvement in treatment and supportive care over the past few decades, coupled with expanded prophylaxis and prevention regimens, have led to reduction in both the frequency and severity of infections.
Journal ArticleDOI
Voriconazole in hematopoietic stem cell transplantation and cellular therapies: Real-world usage and therapeutic level attainment at a major transplant center.
Julian Lindsay,Elizabeth M Krantz,J. Morris,Ania Sweet,Frank P. Tverdek,Avadhut D. Joshi,Rosa F. Yeh,Joshua A. Hill,Matthew Greenwood,Sharon C.-A. Chen,David C. M. Kong,Monica A. Slavin,Steven A. Pergam,Catherine Liu +13 more
TL;DR: Voriconazole (VCZ) was one of the first mold-active triazoles available; however, its current use among high-risk hematology populations is unknown as mentioned in this paper .
Journal ArticleDOI
Antibiotic Exposure Prior to Respiratory Viral Infection is Associated with Disease Progression to Lower Respiratory Tract Infection in Allogeneic Hematopoietic Cell Transplantation Recipients
Chikara Ogimi,Jonathan L. Golob,Elizabeth M Krantz,Alpana Waghmare,Catherine Liu,Wendy M. Leisenring,Hu Xie,Zach Stednick,Christopher R. Woodard,Sara Marquis,Elizabeth Nguyen,Lisa Chung,Sonia Goyal,Louise E. Kimball,Jane Kuypers,Keith R. Jerome,Steven A. Pergam,David N. Fredricks,Janet A. Englund,Michael Boeckh +19 more